SUMMARY
# Combination Therapy Sequencing in Parkinson's Disease
## Background and Rationale
This translational validation study systematically evaluates optimal sequencing and combination strategies for disease-modifying therapies in Parkinson's disease, addressing the critical clinical need for rational polytherapy approaches. The experiment employs both preclinical models and human biomarker studies to determine synergistic combinations of neuroprotective agents targeting complementary pathways includ
METHODOLOGY NOTES
**Phase 1: Patient Recruitment and Baseline Assessment (Weeks 1-4)**
• Recruit 240 Parkinson's disease patients (Hoehn & Yahr stages 2-3) from multiple clinical centers
• Obtain informed consent and verify inclusion criteria: age 50-75, confirmed PD diagnosis >2 years, stable on levodopa ≥3 months
• Exclude patients with atypical parkinsonism, dementia (MoCA <26), or recent deep brain stimulation
• Randomize patients into 4 groups (n=60 each): Group A (levodopa→dopamine agonist→MAO-B inhibitor), Group B (dopamine agonist→levodopa→MAO-B inhibitor), Group C (MAO-B inhibitor→levodopa→dopamine agonist), Group D (standard care control)
• Conduct baseline assessments: UPDRS Parts I-IV, Parkinson's Disease Questionnaire-39 (PDQ-39), levodopa equivalent daily dose (LEDD), and motor fluctuation diary
**Phase 2: First Treatment Intervention (Weeks 5-16)**
• Initiate first therapy according to randomization sequence
• Titrate medications over 4 weeks to optimal therapeutic dose based on clinical